See all the latest news, blogs and updates from the medical sector.
Bringing people together | The Big Give Christmas Challenge 2026
For individuals and families living with MPS, Fabry and related rare conditions, meeting up with someone who truly understands makes an extraordinary difference.
A tribute to Prof Donald Robinson
Professor Donald Robinson, who carried out pioneering research into the basic causes of lysosomal storage diseases, including MPS, died on September 17th 2026 aged 99.
Update on UK process for exploring international access to FAYUVI
There is no formal NHS pathway to access FAYUVI, which remains an investigational gene therapy in the UK. This article outlines the process a family could take to explore privately funded access to FAYUVI.
Together we can transform lives
Our amazing fundraiser have been super busy this summer. From boxing, skydiving, footy and superheroes, it's time to catch up on the latest fundraising round-up.
UK MPS Society welcomes FDA approval of UX111 for MPS IIIA
The UK MPS Society welcomes the news that the US Food and Drug Administration (FDA) has approved UX111 for the treatment of paediatric patients with Mucopolysaccharidosis Type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A
New children's book launches to save children like Leni
Little Leni has the most adorable laugh. She is curious, funny and full of energy! But Leni has a big struggle ahead of her. Every penny from this book, based on Leni's story, will help raise awareness of Childhood Dementia in the UK.
SMC final review approves life-changing gene therapy for treating MLD
We are delighted to announce that the SMC has recently undertaken its final review of atidarsagene autotemcel (Libmeldy®) and has given a positive recommendation for its use within NHS Scotland.
A new chapter for Sophie
Since recently stepping into the role of Interim CEO, Sophie Thomas reflects on her journey with the MPS Society so far and explains her commitment for her next chapter with the charity.
Fabrazyme supply update for our Fabry community
We are sharing an update about the supply of Fabrazyme. You may already be aware that the FDA has raised concerns following a review of Sanofi’s manufacturing site in Ireland and we understand that uncertainty about treatment can be unsettling.
Regulatory update on RGX-121 for MPS II Hunter
Regenxbio have today issued an announcement about its investigational gene therapy RGX-121 for MPS II Hunter syndrome.